The stock of Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) has decreased by -6.76 when compared to last closing price of 0.73. Despite this, the company has experienced a -26.18% fall in its stock price over the last five trading sessions. zacks.com reported 2025-05-08 that Ironwood incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year.
Is It Worth Investing in Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Right Now?
Company’s 36-month beta value is 0.31.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for IRWD is 156.66M, and currently, short sellers hold a 5.62% ratio of that floaft. The average trading volume of IRWD on May 14, 2025 was 3.18M shares.
IRWD’s Market Performance
IRWD stock saw a decrease of -26.18% in the past week, with a monthly decline of -27.64% and a quarterly a decrease of -63.61%. The volatility ratio for the week is 14.19%, and the volatility levels for the last 30 days are 13.70% for Ironwood Pharmaceuticals Inc (IRWD). The simple moving average for the last 20 days is -16.18% for IRWD stock, with a simple moving average of -79.14% for the last 200 days.
IRWD Trading at -40.64% from the 50-Day Moving Average
After a stumble in the market that brought IRWD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.37% of loss for the given period.
Volatility was left at 13.70%, however, over the last 30 days, the volatility rate increased by 14.19%, as shares surge +5.60% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -54.99% lower at present.
During the last 5 trading sessions, IRWD fell by -26.43%, which changed the moving average for the period of 200-days by -89.92% in comparison to the 20-day moving average, which settled at $0.8164. In addition, Ironwood Pharmaceuticals Inc saw -84.56% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IRWD starting from MCCOURT Thomas A, who sale 139,064 shares at the price of $1.76 back on Feb 10 ’25. After this action, MCCOURT Thomas A now owns 1,160,634 shares of Ironwood Pharmaceuticals Inc, valued at $244,753 using the latest closing price.
Silver Ronald, the Principal Accounting Officer of Ironwood Pharmaceuticals Inc, sale 12,048 shares at $1.76 during a trade that took place back on Feb 10 ’25, which means that Silver Ronald is holding 279,655 shares at $21,204 based on the most recent closing price.
Stock Fundamentals for IRWD
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.87 for the gross margin
The net margin for Ironwood Pharmaceuticals Inc stands at -0.01. The total capital return value is set at 0.2. Equity return is now at value -559.14, with -8.20 for asset returns.
Based on Ironwood Pharmaceuticals Inc (IRWD), the company’s capital structure generated 0.76 points at debt to capital in total, while cash flow to debt ratio is standing at 0.48. The debt to equity ratio resting at 3.14. The interest coverage ratio of the stock is 3.11.
Currently, EBITDA for the company is 100.24 million with net debt to EBITDA at 1.77. When we switch over and look at the enterprise to sales, we see a ratio of 0.68. The receivables turnover for the company is 7.99for trailing twelve months and the total asset turnover is 0.97. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.34.
Conclusion
In a nutshell, Ironwood Pharmaceuticals Inc (IRWD) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
